Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Increased number of shares and votes in BillerudKorsnäs

The number of shares and votes in BillerudKorsnäs Aktiebolag (publ) has during July increased with 41,391,588 due to the rights issue resolved upon by the Board of Directors on 25 May 2022 with authorisation from the Annual General Meeting held on 10 May 2022. As of today, the last trading day of the month, there are in total 249,611,422 shares and votes in the company. BillerudKorsnäs holds 1,261,891 shares in treasury. For more information, please contact:Ivar Vatne, CFO, +46 8 553 335 07   This information is of such character, which BillerudKorsnäs Aktiebolag (publ) shall

INVISIO receives volume order for its Intercom system

INVISIO is receiving a major order for its Intercom system, where the customer is a European NATO country. The order is valued at SEK 13 million. The order is a significant reference order for the new Intercom system and the company estimates that the future needs of the customer may lead to further major orders. The systems are to be delivered during the third quarter of 2022 and the combined value is SEK 13 million. “The order confirms our assessment that the Intercom system will generate considerable revenue in the not-too-distant future. There is great interest in the new

Elkem ASA – Mandatory notification of trade – primary insider

Oslo, 29 July 2022 Luiz Simao, SVP Carbon Solutions in Elkem ASA (OSE ticker code: "ELK"), has on 29 July 2022 sold 10,000 shares in Elkem ASA at an average price of NOK 39.72 per share. Following this transaction Luiz Simao holds 650,000 options in Elkem ASA. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Odd-Geir LyngstadVP Finance & Investor RelationsTel: +47 976 72 806Email: odd-geir.lyngstad@elkem.com About ElkemElkem is one of the world’s leading

Invitation to press and analyst conference

Holmen’s interim report for January–June 2022 will be published at 07.30 CEST on Friday 19 August. In view of this, you are invited to watch the online broadcast of our press and analyst conference on the same day at 09.00 CEST. Time: 19 August at 09.00 CESTOnline broadcast: www.holmen.com/reports Holmen President and CEO Henrik Sjölund, together with CFO Anders Jernhall, will present and comment on the report. The presentation will be held in English. You may also participate in the conference by telephone, by calling: +46 8 505 100 31 (within Sweden)+44 207 107 06 13 (from

Notification of reduction share of capital in JM AB (publ)

JM has received permission by the Swedish Companies Registration Office to effect the reduction of share capital with SEK 1,477,650 regarding 1,477,650 shares as per July 14, 2022 decided at the Annual General Meeting on March 31, 2022. In accordance with Chapter 4, section 9 of the Financial Instruments Trading Act information about the total number of shares is to be announced on the final trading day of the month. After the reduction, the share capital amounts to SEK 68,278,841 and the total number of issued shares in JM AB is 68,278,841. Following the transaction JM holds 1,267,500

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 137 - 29 JULY 2022  In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Akelius sells Akelius Technology AB

Akelius Residential Property AB strengthens its focus on residential real estate.Akelius sells Akelius Technology AB which includes the Technology Department to Akelius Apartments Ltd on 2022-07-29. The sales price for shares and shareholder loans is EUR 7.5 million.The valuation was made using the discounted cashflow model. Akelius Residential Property AB continues using the services of Akelius Technology AB. Ralf Spann, CEO - Akelius remains committed to its goal of using tailor made applications. One of the major applications in use is the Tenant Administration

ANNOUNCEMENT OF THE NAV OF P CAPITAL PARTNERS ALPHA

Press release Stockholm, 29 July 2022 Since P Capital Partners Alpha decreased its contributed capital by SEK 13,3 million through a repayment to debenture holders and owners, the Net Asset Value of the P Capital Partners Alpha participation loan has been calculated. The Net Asset Value is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The repayment amounted to SEK 9,000 per participation loan debenture, and SEK 1,4 million to the owners. At the close of business on 28 July 2022, the Net Asset Value of the P Capital

ANNOUNCEMENT OF THE NAV OF P CAPITAL PARTNERS III

Press release Stockholm, 29 July 2022 Since P Capital Partners III decreased its contributed capital by SEK 287.9 million through a repayment to debenture holders and owners, the Net Asset Value of the P Capital Partners III participation loan has been calculated. The Net Asset Value is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The repayment amounted to SEK 25,000 per Series A participation loan debenture, SEK 625,000 per Series B participation loan debenture and SEK 31.8 million to the owners. At the close of business

Atlas Copco has acquired a compressor distributor in Georgia, USA

Nacka, Sweden, July 29, 2022: Atlas Copco has acquired the operating assets of Compressed Air Products, Inc. (CAP). CAP sells to a broad range of industrial customer segments. It also has a strong service business.CAP is located in Newnan, Georgia, south-west of Atlanta, and has 20 employees. “CAP has a strong reputation in the Georgia market,” said Vagner Rego, Business Area President Compressor Technique. “We have a long relationship with CAP as a distributor. This acquisition is in line with our strategy to get closer to our customers.” The purchase price is not disclosed. The

Paratus Energy Services Ltd Announces Trading Update for First Quarter 2022 and Other Updates

Hamilton, Bermuda, July 29, 2022 - Paratus Energy Services Ltd. (“Paratus” or the “Company”) today announced a trading update for the first quarter 2022 and updates on Paratus, its subsidiaries, and associated companies (“Paratus Group”). 1. Key Financial Highlights 1.1    Paratus In the first quarter ending March 31, 2022, Paratus generated $54 million in revenue and $29 million in EBITDA[1]. As a result of the pre-packaged Chapter 11 restructuring on January 20, 2022, comparisons of revenue and EBITDA to the preceding quarter are not meaningful. 1.2    SeaMex Group During

HALF YEAR REPORT, SECOND QUARTER 2022

  Press release: Stockholm, July 29, 2022, 08.45 CET HIGHLIGHTS OF THE SECOND QUARTER 2022 · Net sales was 90 MSEK compared to the previous year 109 MSEK. Decrease was due to declined silver price and lower production · EBITDA was 6 MSEK (36) · EBIT was -16 MSEK (16) · Cash and cash equivalents were 43 MSEK (52) · Investments were 24 MSEK (5) · The production was about 281 000 (382 000) ounces of silver, 796 (988) ounces of gold, 365 (396) tonnes of lead, and 824 (919) tonnes of zinc in concentrates · New mining contract was signed with Veljekset

SOTKAMO SILVER AB: UPDATED GUIDANCE FOR SILVER PRODUCTION IN 2022

Press release: Stockholm, July 29, 2022, 08:45 CET Sotkamo Silver AB revises the estimate for silver production in 2022. The updated guidance is based on the silver production of 617 koz until the end of the second quarter, and updated production schedule for the second half of the year. The production volumes of gold, zinc and lead have been at the same level or exceeded the volumes during the same period last year. New production guidance for 2022: We continue to focus on the production mix and optimization of the revenue and operative cashflow. Consequently, we estimate that our

Idogen is preparing to start the clinical phase 1/2a study with IDO 8 in Norway

Idogen AB (publ) is working intensively on the preparations for the company's first clinical study with the cell therapy IDO 8 in patients with severe hemophilia A and is meeting a great deal of commitment at participating study centers. In Norway, the company's clinical trial center has come a long way in preparations for the study.   Idogen has previously received approval from both the Swedish and the Norwegian Medicines Agency to start the study, and in Norway, patients who are suitable for inclusion have now been identified. Professor Pål Andre Holme, senior physician at Oslo

Sleep Cycle interim report April-June 2022 - Stable growth and strong operating margin

The positive development from the start of the year continued in the second quarter. Net sales increased by 19.0%, equivalent to an increase of 16.1% adjusted for currency effects. The operating margin increased to 24.4% thanks to effective cost control and growth in revenue. The total number of users increased but was impacted by seasonal variations and price adjustments. As anticipated, new user acquisition was only partially affected by the price adjustments, resulting in an overall higher sales value.Second quarter summary (April-June 2022) · Net sales increased by 19.0% (12.5)%

BioStock: Norwegian doctors prepare for Idogen’s study

Biotech company Idogen is in full swing with preparations for the first clinical study with the cell therapy IDO 8 in patients with severe haemophilia A. BioStock had the opportunity to interview Professor Pål André Holme, Chief Physician at Oslo University Hospital and Clinical Investigator in Idogen’s study, and Dag Josefsen, who is Chief Physician and Head of Department at the Section of Cell Therapy.Read the full article at biostock.se: https://www.biostock.se/en/2022/07/norwegian-doctors-prepare-for-idogens-study/ This is a press release from BioStock - Connecting Innovation &

Chair succession

29 July 2022 07:01 BST Michel Demaré to succeed Leif Johansson as Non-Executive Chair of the Board AstraZeneca PLC today announced the appointment of Michel Demaré as the Chair-designate of the Board. His appointment followed a robust succession planning process led by Philip Broadley in his capacity as senior independent Non-Executive Director. As previously communicated, Leif Johansson, current Chair of the Board of AstraZeneca will be retiring at the conclusion of the Company's Annual General Meeting in April 2023.  Michel's appointment will take effect immediately on Leif'

Axolot Solutions Holding AB (publ) - Interim report January-June 2022

Successful trials at Aspa Bruk, letter of intent signed regarding the Norwegian market and oversubscribed preferential rights issue completed.Summary of the second quarter 2022 Financially · Net sales amounted to 350 tSEK (529 tSEK for the corresponding quarter in 2021), which refers to customer trial activities and studies. · Other revenues were 0 tSEK (60), where the revenue in the comparison period relates to public research grants and project support. · Earnings before interest and tax became -5 108 tSEK (-4 954), that is relatively unchanged. · Net earnings per share

Number of shares and votes in Oncopeptides

Stockholm, Sweden — July 29, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s share issue as announced on July 14, 2022. As a result of the share issue, the number of outstanding shares and votes has increased by 15,061,443 from 75,307,217 to 90,368,660. The share capital has increased by approximately SEK 1,673,494 from SEK 8,367,469 to SEK 10,040,963.For further

SkartaNYAB Oyj - Managers' Transactions

SkartaNYAB PlcMANAGERS' TRANSACTIONS29 July 2022 at 09:00SkartaNYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive Officer Issuer: SkartaNYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 18114/5/6____________________________________________

Conversion of shares in Skanska AB

According to Skanska AB’s articles of association, holders of Series A shares are entitled to submit requests to the company for conversion of their shares to Series B shares. Such conversion reduces the total number of votes in the company.In conjunction with a conversion of shares, the company is obliged according to the Swedish Financial Instruments Trading Act (1991:980) to disclose information concerning the change. During July 2022, 931 Series A shares were converted to Series B shares at the request of shareholders. Accordingly, the total number of votes in the company thereafter

There are no items matching the current filter
There are no more items matching the current filter
Back to top